Management of persistent allergic rhinitis: evidence-based treatment with levocetirizine

Joaquim Mullol1
Claus Bachert2
Jean Bousquet3

1Unitat de Rinologia, Servei d’Otorinolaringologia, ICMEQ, Hospital Clinic, IDIBAPS, Barcelona, Spain; 2Department of Oto-Rhino-Laryngology, University Hospital, Ghent, Belgium; 3Clinique des Maladies Respiratoires, University Hospital and INSERM U454, Hospital Arnaud de Villeneuve, CHU Montpellier, France

Abstract: Allergic rhinitis (AR) is a major health problem that can significantly impair quality of life (QoL). The former classification of AR comprises seasonal allergic rhinitis (SAR) and perennial allergic rhinitis (PAR), which do not adequately reflect the clinical course and presentation of AR. The Allergic Rhinitis and its Impact on Asthma (ARIA) classification is based on the duration of symptoms and their severity. Persistent AR (PER) is experienced for periods longer than 4 days/week and for more than 4 consecutive weeks, and may feature mild or moderate-to-severe disease based on the impairment of QoL and symptom severity. Oral antihistamines are a standard treatment option in AR. New second generation antihistamines have a rapid onset of action, are highly effective on AR symptoms, and some were even shown to relieve nasal congestion. Levocetirizine is a potent histamine H1-receptor antagonist with proven efficacy in both SAR and PAR, and it is the best studied therapeutic option in persistent AR. The Xyzal in Persistent Rhinitis Trial (XPERT™) studied 551 patients with PER, showing that levocetirizine (5 mg/day compared with placebo) significantly improved nasal symptoms as early as the first week and for the 6 months of study, with significant improvement in nasal congestion after 6 weeks of treatment. Levocetirizine also improved QoL, was well tolerated, and produced substantial societal and employer cost savings. Thus, levocetirizine is the first tested standard treatment for PER using ARIA classification, and shows prompt short-term and long-term relief of symptoms, improves patients’ QoL, and provides economic benefits to employers and the society.

Keywords: allergic rhinitis, antihistamines, levocetirizine, quality of life, societal costs

Introduction
Allergic rhinitis (AR) is a major health problem with high and ever-increasing prevalence (Bousquet et al 2001). At least one in five adults in Western Europe are estimated to have AR (Bauchau and Durham 2004), and its well-known nasal and eye symptoms can be severe enough to have a substantial negative impact on daily activities and sleep, with resulting impairment of quality of life (QoL) similar to that caused by asthma (Bousquet, Bullinger et al 1994; Bousquet, Knani et al 1994). Despite the debilitating effects of AR, it remains a condition where patients do not seek appropriate treatment, are undertreated, or do not adhere to treatment; all of which lead to high societal costs (Malone et al 1997; Schoenwetter et al 2004). A recent study found a total cost of about €350 per month, mainly due to reduced productivity, for each AR patient who had not received appropriate long-term therapy for their condition (Bousquet et al 2005). Therefore, there is a need to radically improve diagnosis, treatment, and management of AR.

Allergic rhinitis and its impact on asthma
The former classification of AR comprised seasonal allergic rhinitis (SAR), which was mainly linked to pollen allergy, and perennial allergic rhinitis (PAR), which was...
mainly linked to house-dust mites. Many shortcomings of this classification have become apparent over the years. For example, many AR patients are polysensitized to pollen and perennial allergens (Bauchau and Durham 2005), and thus cannot be classed as having SAR or PAR. Also, some countries have seasonal pollen, while others have pollen for many months, or even perennially (Bousquet et al 2001). Finally, the SAR/PAR classification does not cover severity or duration of the disease, which makes it difficult to decide upon the best treatment option.

The Allergic Rhinitis and its Impact on Asthma (ARIA) classification system was introduced in 2001 and is based on duration and severity of symptoms and their impact on QoL (Figure 1) (Bousquet et al 2001). The duration of AR is split into intermittent and persistent patterns. Intermittent AR is defined by symptoms that occur for 4 or less days per week or for not more than 4 consecutive weeks, whereas persistent AR (PER) lasts for more than 4 days per week and for more than 4 consecutive weeks. Symptoms of intermittent AR or PER may be mild or moderate-to-severe based on its impact on QoL and symptom severity. Mild rhinitis characteristically does not affect daily, leisure, or sport activities, normal work or school attendance, or disturb sleep, and causes no bothersome symptoms. Moderate-to-severe rhinitis is characterized by impairment of at least one of these parameters. Compared with patients with intermittent AR, PER patients had more severe symptoms, a higher rate of self awareness, previous diagnosis of AR, differed in their use of medication, and had a clearly distinct allergen sensitization pattern (Bauchau and Durham 2005).

The ARIA classification system is distinct from the classic one. Patients classified as having SAR do not necessarily have intermittent AR, and PAR-classified patients do not always have PER (Bauchau and Durham 2005). In one study, nearly half of so-called SAR patients had PER, and nearly half of PAR patients had only intermittent AR (Demoly et al 2003; Bauchau and Durham 2005). Another feature of ARIA is that it acknowledges the relationship of AR with asthma and other comorbidities such as rhinosinusitis and conjunctivitis, and recommends a combined treatment strategy of upper and lower Airways for optimum management (Bousquet et al 2001).

**PER management**

PER is managed on different levels and includes allergen avoidance, immunotherapy, pharmaceutical treatment, and patient education (Bousquet et al 2001). Allergen avoidance measures should always be indicated when possible and appear to be effective, although the level of scientific evidence is low (Bousquet et al 2001). Allergen avoidance can be difficult because patients are often sensitised to many allergens, and it may impact negatively on daily activities, family life, and QoL (Martin 1999; Morris 2004). Examples of avoidance measures include removal of carpets, regular vacuuming, regular washing of bedclothes, use of dust mite-resistant covers, removal of pets, and staying inside during high pollen loads (Bousquet et al 2001; Horak et al 2004; Peat et al 2004; van den Bemt et al 2004; Simpson and Custovic 2005).

Allergen immunotherapy may be suitable in PER patients who have severe or long-term symptoms predominantly induced by dominating allergens. ARIA recommends allergen immunotherapy in carefully selected patients with rhinitis (especially when complicated by asthma) and specific sensitivities, and in patients in whom pharmacotherapy produces incomplete symptom control or undesirable adverse events (Bousquet et al 2001; Durham et al 1999). It should be initiated early in the disease process to reduce the risk of adverse events and to prevent the further development of severe disease as it may alter the course of disease and prevent asthma. It can be given subcutaneously and is effective; however, it is time consuming, costly, and carries a low risk of anaphylaxis (Bousquet et al 2001). Sublingual administration has a lower risk of anaphylaxis.
and is less time-consuming than subcutaneous administration, but it may have lower efficacy and requires good compliance by the patient (Bousquet et al 2001; Wilson et al 2005).

Pharmacotherapeutic options include oral antihistamines, and topical antihistamines that can be administered in the nose. According to ARIA, antihistamines are recommended for all types of intermittent rhinitis and mild persistent rhinitis; in severe persistent rhinitis, intranasal steroids are the first-line treatment due to their higher efficacy in treating nasal obstruction, and they may be complemented by antihistamines as add-on treatment if required (Bousquet et al 2003; Simons 2004).

Compared with older antihistamines, newer antihistamines have rapid onset of action (minutes to hours), are easy to use, and are highly effective on symptoms such as rhinorrhea, sneezing, and nasal and ocular pruritus. They are mostly free of anticholinergic adverse effects and relatively safe compared with first generation antihistamines, even in population groups such as the elderly (Hansen et al 2005). Furthermore, the newer agents are comparatively nonsedating, thus providing further benefit over older antihistamines with sedative properties that are no longer recommended in adults or in children (Kay 2000).

It was shown in PER that local inflammation is closely linked to nasal obstruction and airflow (Ciprandi et al 2005a). So the antiinflammatory activities exerted by some modern antihistamines may explain the efficacy on nasal obstruction and decongestant effects found in some antihistamines like levocetirizine (Ciprandi et al 2005a). In addition, antihistamines may reduce symptoms of AR and asthma in patients with comorbid diseases (Simons 2002, 2004; Bachert and Demarteau 2005). The antiinflammatory effect of newer antihistamines is gaining significance in allergic conditions where inflammation might occur and lead to asthma (Simons 2004). For example, in the Early Treatment of the Atopic Child (ETAC™) study, the antihistamine cetirizine has been shown to prevent the atopic march from atopic dermatitis to asthma in patients sensitized to grass pollen or house-dust mite (Warner 2001). This interesting result is being investigated in the Early Prevention of Asthma in Atopic Children (EPAAC™) study with levocetirizine (Fumagalli et al 2004).

Levocetirizine 5 mg once daily was established as the most effective and well tolerated dose, producing significant improvements in AR symptoms compared with placebo in a study of 470 patients with SAR (Leynadier et al 2001). A further placebo comparison in 294 patients with PAR showed it produced rapid and significant improvements in AR symptoms within the first week of treatment, which were maintained throughout a 6-week treatment period (Potter 2003). Interestingly, nasal congestion was also significantly reduced in the levocetirizine group compared with placebo over the treatment period with significance within the first
Levocetirizine in PER

The above studies were performed in a variety of patients with AR classified by the classic system in SAR and PAR. It is difficult to guess how this evidence can be translated into the new indication PER because PER patients are different from SAR or PAR patients. That is why it is of clinical relevance to study rhinitis medication in patients with PER. As of today, few studies have been performed with antihistamines or nasal steroids in PER, although the ARIA classification has been adopted by the industry and academia. Most of these studies were done with levocetirizine. There have been even fewer studies performed in intermittent rhinitis, and there is no evidence yet for levocetirizine in this indication.

A pilot study in 40 patients with PER showed that levocetirizine 5 mg/day for 4 weeks improved nasal symptoms, including nasal obstruction, and increased total nasal airflow (Ciprandi et al 2005a). In addition, levocetirizine showed decongestant effects by decreasing the reversibility of nasal airflow after application of a potent alpha-adrenostimulator.

The only major clinical trial to assess any agent as a standard treatment option for PER is the Xyzal in Persistent Rhinitis Trial (XPERT™) (Bachert et al 2004), a 6-month, double-blind, placebo-controlled multicenter trial of 551 patients with PER who received levocetirizine 5 mg/day or placebo. The study assessed individual symptoms, QoL (both general and disease-specific), comorbidities, pharmacoeconomics, and safety (Bachert et al 2004).

Results from XPERT showed that levocetirizine significantly improved nasal and ocular symptoms compared with placebo as early as 1 week after starting treatment and this improvement was maintained over the 6-month period of study (Figure 2). Notably, significant improvement in nasal congestion was observed versus placebo after the first month of treatment and maintained over 6 months (p < 0.05 for months 2–6) (Van Cauwenberge et al 2005), which the authors attributed to the long-term antiinflammatory action of levocetirizine (Bachert et al 2004). Levocetirizine also improved QoL (assessed by Rhinoconjunctivitis Quality of Life Questionnaire and Short-Form 36), and was well tolerated (Bachert et al 2004) (Figure 3). An economic analysis showed the relatively low cost of long-term levocetirizine therapy compared with the substantial cost of untreated PER and its comorbidities (€350/patient/month). Levocetirizine treatment produced cost savings to society of more than €150/patient/month, mainly due to...
Levocetirizine in persistent allergic rhinitis

patients being able to maintain work ability and daily activities (Bousquet et al 2005). In an exploratory analysis of the XPERT study, levocetirizine reduced the percentage of patients with at least one asthma event to 7.4 (from 13.6 for placebo, p = 0.04) and reduced the mean number of asthma medication events from 0.23 per placebo patient to 0.11 (p < 0.001) (Bachert and Demarteau 2005).

Conclusion
ARIA defines AR as intermittent AR or PER, based on symptom duration and severity. It complements the classic SAR/PAR classification, and clearly defines PER as different from PAR. Long-term studies in PER will be able to show the effect of drug therapy on allergic symptoms, including nasal congestion. Levocetirizine is currently the best studied treatment in intermittent rhinitis, although studies in intermittent rhinitis are still lacking. XPERT showed that over a period of 6 months, levocetirizine was effective against PER symptoms (including nasal congestion), improved QoL, reduced the incidence of comorbidities like asthma, and reduced societal costs. These results show that assessment of drug efficacy and tolerability according to ARIA is clinically relevant, and that significant benefit may be achieved with long-term treatment of PER with levocetirizine.
References

Bachert C, Bousquet J, Canonica GW, et al. 2004. Levocetirizine improves quality of life and reduces costs in long-term management of persistent allergic rhinitis. *J Allergy Clin Immunol*, 114:838–44.

Bachert C, Demarteaux N. 2005. Levocetirizine reduces asthma comorbidity in patients with persistent allergic rhinitis: an exploratory analysis of the XPERT™ trial. *Allergy Clin Immunol Int*, S1:100–1.

Baucau V, Durham SR. 2004. Prevalence and rate of diagnosis of allergic rhinitis in Europe. *Eur Respir J*, 24:758–64.

Baucau V, Durham SR. 2005. Epidemiological characterization of the intermittent and persistent types of allergic rhinitis. *Allergy*, 60:350–3.

Bousquet J, Bullinger M, Fayol C, et al. 1994. Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. *J Allergy Clin Immunol*, 94:182–8.

Bousquet J, Demarteaux N, Mullol J, et al. 2005. Costs associated with persistent allergic rhinitis are reduced by levocetirizine. *Allergy*, 60:788–94.

Bousquet J, Knani J, Dhivert H, et al. 1994. Quality of life in asthma. I. Internal consistency and validity of the SF-36 questionnaire. *Am J Respir Crit Care Med*, 149:371–5.

Bousquet J, Van Cauwenberge P, Bachert C, et al. 2003. Requirements for medications commonly used in the treatment of allergic rhinitis. *Allergy*, 58:192–7.

Bousquet J, Van Cauwenberge P, Khaltaev N. 2001. Allergic rhinitis and its impact on asthma. *J Allergy Clin Immunol*, 108:S147–334.

Ciebiada M, Gorska-Ciebiada M, DuBuske LM, et al. 2005. Montelukast and levocetirizine in the treatment of perennial allergic rhinitis: a randomised, double-blind, placebo-controlled study. *Allergy Clin Immunol Int*, S1:264.

Ciprandi G, Cirillo I, Vizzaccaro A, et al. 2004. Levocetirizine improves nasal obstruction and modulates cytokine pattern in patients with seasonal allergic rhinitis: a pilot study. *Clin Exp Allergy*, 34:958–64.

Ciprandi G, Cirillo I, Vizzaccaro A, et al. 2005a. Levocetirizine improves nasal symptoms and airflow in patients with persistent allergic rhinitis: a pilot study. *Allergy Immunol (Paris)*, 37:25–9.

Ciprandi G, Cirillo I, Vizzaccaro A, et al. 2005b. Desloratadine and levocetirizine improve nasal symptoms, airflow, and allergic inflammation in patients with perennial allergic rhinitis: A pilot study. *Int Immunopharmacol*, in press.

Ciprandi G, Marseglia GL, Klersy C, et al. 2005. Relationships between allergic inflammation and nasal airflow in children with persistent allergic rhinitis due to mite sensitization. *Allergy*, 60:957–60.

Clough GF, Boutsiouki P, Church MK. 2001. Comparison of the effects of levocetirizine and loratadine on histamine-induced wheal, flare, and itch in human skin. *Allergy*, 56:985–8.

Day JH, Briscoe MP, Rafeino E, et al. 2004. Comparative clinical efficacy, onset and duration of action of levocetirizine and desloratadine for randomised, seasonal allergic rhinitis in subjects evaluated in the Environmental Exposure Unit (EEU). *Int J Clin Pract*, 58:109–18.

de Blie J, Wahn U, Billard E, et al. 2005. Levocetirizine in children: evidenced efficacy and safety in a 6-week randomized seasonal allergic rhinitis trial. *Pediatr Allergy Immunol*, 16:267–75.

Demoly P, Allaert FA, Lecasble M, et al. 2003. Validation of the classification of ARIA (Allergic Rhinitis and its Impact on Asthma). *Allergy*, 58:672–5.

Deruaz C, Leimgrubner A, Berney M, et al. 2004. Levocetirizine better protects than desloratadine in a nasal provocation with allergen. *J Allergy Clin Immunol*, 113:669–76.

Devalia JL, De Vos C, Hanotte F, et al. 2001. A randomized, double-blind, crossover comparison among cetirizine, levocetirizine, and ucb 28557 on histamine-induced cutaneous responses in healthy adult volunteers. *Allergy*, 56:50–7.

Durham SR, Walker SM, Varga EM, et al. 1999. Long-term clinical efficacy of grass-pollen immunotherapy. *New Engl J Med*, 341:468–75.

Fumagalli F, Baiardini I, Pasquali M, et al. 2004. Antihistamines: do they work? Further well-controlled trials involving larger samples are needed. *Allergy*, 59(Suppl 78):74–7.

Gandon JM, Allain H. 2002. Lack of effect of single and repeated doses of levocetirizine, a new antihistamine drug, on cognitive and psychomotor functions in healthy volunteers. *Br J Clin Pharmacol*, 54:51–8.

Giustizieri ML, Alabanesi C, Flhirj J, et al. 2004. H1 histamine receptor mediates inflammatory responses in human keratinocytes. *J Allergy Clin Immunol*, 114:1176–82.

Grant JA, Riethuisen JM, Moulaut B, et al. 2002. A double-blind, randomized, single-dose, crossover comparison of levocetirizine with ebastine, fexofenadine, loratadine, mizolastine, and placebo: suppression of histamine-induced wheal-and-flare response during 24 hours in healthy male subjects. *Ann Allergy Asthma Immunol*, 88:190–7.

Hansen J, Klimek L, Hörmann K. 2005. Pharmacological management of allergic rhinitis in the elderly: safety issues with oral antihistamines. *Drugs Aging*, 22(Suppl 4):289–96.

Horak F Jr, Matthews S, Horst G, et al. 2004. Effect of mite-impermeable mattress encasings and an educational package on the development of allergies in a multinational randomized, controlled birth-cohort study – 24 months results of the Study of Prevention of Allergy in Children in Europe. *Clin Exp Allergy*, 34:1220–5.

Horak F, Ziegelmayer P, Ziegelmayer R, et al. 2005. Levocetirizine has a longer duration of action on improving total nasal symptoms score than fexofenadine after single administration. *Br J Clin Pharmacol*, 60:24–31.

Kay GG. 2000. The effects of antihistamines on cognition and performance. *J Allergy Clin Immunol*, 105:S622–7.

Lombardo G, Quattrocci P, Lombardo GR. 2005. Levocetirizine and montelukast in the treatment of seasonal allergic rhinitis. *Eur Respir J*, 26(Suppl 49):137s.

Leynadier F, Mees K, Arendt C, et al. 2001. Efficacy and safety of levocetirizine in seasonal allergic rhinitis. *Acta Otorhinolaryngol Belg*, 55:305–12.

Malone DC, Lawson KA, Smith DH, et al. 1997. A cost of illness study of allergic rhinitis in the United States. *J Allergy Clin Immunol*, 99:22–7.

Martin IR. 1999. The feasibility of allergen avoidance: compliance and effect on quality of life of a house dust mite allergen avoidance strategy for families with asthma. University of Otago Public Health Group [online]. Accessed 13 June 2005. URL: http://www chmeds ac nz work? Further well-controlled trials involving larger samples are needed.

Michel L, Jean-Louis F, Dubrettel L. 2001. Pharmacological study of levocetirizine in IgE-dependent hypersensitivity cutaneous reaction in grass pollen allergic volunteers: Demonstration of mediator release and eosinophil recruitment modulation by levocetirizine. *Allergy*, 56(Suppl 68):150–1.

Morris A. 2004. Talking to patients about managing their allergies. *Prescriber*, 15:14–23.

Nathan RA. 2003. Pharmacotherapy for allergic rhinitis: a critical review of leukotriene receptor antagonists compared with other treatments. *Ann Allergy Asthma Immunol*, 90:182–90.

Peat JK, Mihirshahi S, Kemp AS, et al. 2004. Three-year outcomes of dietary fatty acid modification and house dust mite reduction in the Childhood Asthma Prevention Study. *J Allergy Clin Immunol*, 114:807–13.

Potter PC. 2003. Levocetirizine is effective for symptom relief including nasal congestion in adolescent and adult (PAR) sensitized to house dust mites. *Allergy*, 58:893–9.

Schoenwetter WF, Dupclay L Jr, Appajosyula S, et al. 2004. Economic impact and quality-of-life burden of allergic rhinitis. *Curr Med Res Opin*, 20:305–17.

Simons FE. 2002. H1-antihistamines in children. *Clin Allergy Immunol*, 17:437–64.
Simons FE. 2004. Advances in H1-antihistamines. N Engl J Med, 351:2203–17.
Simpson A, Custovic A. 2005. The role of allergen avoidance in the secondary prevention of atopic disorders. Curr Opin Allergy Clin Immunol, 5:223–7.
Stübner P, Zieglmayer R, Horak F. 2004. A direct comparison of the efficacy of antihistamines in SAR and PAR: randomised, placebo-controlled studies with levocetirizine and loratadine using an environmental exposure unit – the Vienna Challenge Chamber (VCC). Curr Med Res Opin, 20:891–902.
Thomson L, Blaylock MG, Sexton DW, et al. 2002. Cetirizine and levocetirizine inhibit eotaxin-induced eosinophil transendothelial migration through human dermal or lung microvascular endothelial cells. Clin Exp Allergy, 32:1187–92.
Tillement JP, Testa B, Bree F. 2003. Compared pharmacological characteristics in humans of racemic cetirizine and levocetirizine, two histamine H1-receptor antagonists. Biochem Pharmacol, 66:1123–6.
Van Cauwenberge P. 2005 Efficacy and safety of levocetirizine in persistent allergic rhinitis (PER). Eur Resp J, 26(Suppl 49):136s.
vanden Bemt L, van Knapen L, de Vries MP, et al. 2004. Clinical effectiveness of a mite allergen-impermeable bed-covering system in asthmatic mite-sensitive patients. J Allergy Clin Immunol, 114:858–62.
Warner JO. 2001. A double-blinded, randomized, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis: 18 months’ treatment and 18 months’ posttreatment follow-up. J Allergy Clin Immunol, 108:929–37.
Wilson AM, O’Byrne PM, Parameswaran K. 2004. Leukotriene receptor antagonists for allergic rhinitis: a systematic review and meta-analysis. Am J Med, 116:338–44.
Wilson DR, Lima MT, Durham SR. 2005. Sublingual immunotherapy for allergic rhinitis: systematic review and meta-analysis. Allergy, 60:4–12.
